<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Elevated <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi>-binding protein (LBP), a marker of subclinical endotoxemia, may be involved in the pathogenesis of <z:hpo ids='HP_0001513'>obesity</z:hpo> and metabolic risk </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to investigate the association between plasma LBP and <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> in apparently healthy Chinese </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A population-based study including 559 overweight/<z:mp ids='MP_0001261'>obese</z:mp> (BMI &gt;or=24.0 kg/m(2)) and 500 <z:mpath ids='MPATH_458'>normal</z:mpath>-weight (18.0 &lt;or= BMI &lt;24.0 kg/m(2)) subjects aged 35-54 years was conducted in Shanghai, China </plain></SENT>
<SENT sid="3" pm="."><plain>Fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, LBP, high-sensitivity C-reactive protein, interleukin-6, high-molecular-weight (HMW) adiponectin, leptin, hepatic enzymes, and body composition were measured </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> was defined by the updated National Cholesterol Education Program Adult Treatment Panel III criterion for Asian Americans </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: LBP levels were significantly higher in overweight/<z:mp ids='MP_0001261'>obese</z:mp> individuals than in <z:mpath ids='MPATH_458'>normal</z:mpath>-weight individuals (geometric mean 27.6 [95% CI 25.2-30.3] vs. 10.0 [9.1-11.1] microg/ml; P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>After multiple adjustments including BMI, the odds ratios were 3.54 (95% CI 2.05-6.09) and 5.53 (95% CI 2.64-11.59) for <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, respectively, comparing the highest with the lowest LBP quartile </plain></SENT>
<SENT sid="7" pm="."><plain>Further adjustments for inflammatory markers almost abolished the significant association of LBP with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> but not that with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and controlling for adipokines and hepatic enzymes did not substantially alter the results </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Elevated circulating LBP was associated with <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in apparently healthy Chinese </plain></SENT>
<SENT sid="9" pm="."><plain>These findings suggested a role of <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> via initiation of innate immune mechanism(s) in <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Prospective studies are needed to confirm these results </plain></SENT>
</text></document>